Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 6/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950456 | 1.00 | BTK (0.40) | BTKBDKRB1ALOX5APFEN1GRM2 | |
| SCHEMBL17645694 | 0.86 | BTK (0.43) | BTKBDKRB1ALOX5APFEN1GRM2 | |
| SCHEMBL30950557 | 0.86 | BTK (0.43) | BTKBDKRB1ALOX5APFEN1GRM2 | |
| SCHEMBL17664694 | 0.86 | GRM2 (0.34) | ALOX5APFEN1GRM2 | |
| SCHEMBL17660352 | 0.84 | EPHX2 (0.53) | BTK | |
| SCHEMBL30950537 | 0.80 | BTK (0.61) | BTK | |
| SCHEMBL17660339 | 0.79 | AKT1 (0.34) | BDKRB1ALOX5APFEN1 | |
| SCHEMBL17664647 | 0.79 | KCNA5 (0.39) | — | |
| SCHEMBL21207722 | 0.79 | BTK (0.41) | BTKBDKRB1ALOX5APFEN1GRM2 | |
| SCHEMBL24600491 | 0.77 | BTK (0.48) | BTKGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016057500-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-14 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | BTK 1/4885BDKRB1 928/4885ALOX5AP 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.